<DOC>
	<DOCNO>NCT01791205</DOCNO>
	<brief_summary>This multicenter observational study patient rheumatoid arthritis routine clinical practice Italy . In retrospective Part 1 study , clinical demographic factor associate use biologic drug monotherapy compare therapy combination Disease-modifying anti-rheumatic drug ( DMARDs ) evaluate . In retrospective/prospective Part 2 study , efficacy safety use RoActemra/Actemra ( tocilizumab ) monotherapy evaluate . Patients follow to18 month .</brief_summary>
	<brief_title>ARMONIA : An Observational Study Biologic Drugs Monotherapy Combination With DMARDs Italian Clinical Practice Efficacy Safety RoActemra/Actemra ( Tocilizumab ) Monotherapy Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Part 1 : Adult patient , &gt; /= 18 year age Diagnosis rheumatoid arthritis accord American College Rheumatology ( ACR ) / European League Against Rheumatism ( EULAR ) criterion Patients receive least one cycle biologic therapy , either monotherapy combination , 12 month precede open first site Part 2 : Patients monotherapy RoActemra/Actemra already enrol Part 1 study Patients simultaneously participate study RoActemra/Actemra time sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>